You are here: Industry Insights > Catalent

News List

Exelixis and Catalent Enter ADC Partnership contractpharma
September 17, 2020
Collaboration, license and exclusive option agreement to develop antibody-drug conjugates leveraging SMARTag bioconjugation technology.
Catalent Invests $50M at Bloomington Facility contractpharma
September 03, 2020
To install an additional high-speed vial filling line to support growing pipeline of clinical programs and commercial launches at the site.
Catalent and AstraZeneca Enter Vaccine Manufacturing Deal contractpharma
August 25, 2020
Catalent Inc. will provide drug substance manufacturing to AstraZeneca for the University of Oxford’s adenovirus vector-based COVID-19 vaccine, AZD1222, at Catalent’s commercial gene therapy manufacturing facility located in Harmans, Maryland.
Catalent’s Harmans Site Approved to Manufacture AveXis’ Gene Therapy contractpharma
August 10, 2020
To produce commercial drug substance intermediate for AveXis’ spinal muscular atrophy gene therapy at its manufacturing facility in Harmans, MD.
Catalent Partners with Gene Editing Company Editas contractpharma
July 30, 2020
Will provide services for the development and manufacturing of Editas’ cell and gene medicines.
Catalent Expands Clinical Manufacturing Operations contractpharma
July 22, 2020
Invests $30 million to create European clinical manufacturing center of excellence in Limoges, France.
Catalent, Humanigen Expand Lenzilumab Services Pact contractpharma
July 17, 2020
Catalent will provide development, manufacturing and commercialization services for Humanigen’s GM-CSF monoclonal antibody being studied in COVID-19.
Catalent Completes Purchase of Teva-Takeda Packaging Facility contractpharma
July 02, 2020
The new 60,000-square-foot facility will provide flexible clinical supply solutions, serving both local and global pharma and biopharma companies.
Moderna and Catalent announce collaboration for COVID-19 vaccine candidate expresspharma
June 28, 2020
Catalent to provide vial filling and packaging capacity, as well as additional staffing to support the production of an initial 100 million doses of the vaccine candidate from its facility in Bloomington, Indiana in the US.
Catalent Partners with ViralClear on Potential Treatment for COVID-19 contractpharma
June 23, 2020
Catalent will be developing two oral dosage forms of ViralClear’s broad-spectrum anti-viral agent merimepodib.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 13 Next page